ACYP2 contributes to malignant progression of glioma through promoting Ca2+efflux and subsequently activating c-Myc and STAT3 signals

7Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Acylphosphatase 2 (ACYP2) is involved in cell differentiation, energy metabolism and hydrolysis of intracellular ion pump. It has been reported as a negative regulator in leukemia and a positive regulator in colon cancer, respectively. However, its biological role in glioma remains totally unclear. Methods: We performed quantitative RT-PCR (qRT-PCR), immunohistochemistry (IHC) and western blot assays to evaluate ACYP2 expression. The functions of ACYP2 in glioma cells were determined by a series of in vitro and in vivo experiments, including cell proliferation, colony formation, cell cycle, apoptosis, migration, invasion and nude mouse tumorigenicity assays. In addition, western blot and co-immunoprecipitation (Co-IP) assays were used to identify its downstream targets. Results: Knocking down ACYP2 in glioma cells significantly inhibited cell proliferation, colony formation, migration, invasion and tumorigenic potential in nude mice, and induced cell cycle arrest and apoptosis. Conversely, ectopic expression of ACYP2 in glioma cells dramatically promoted malignant phenotypes of glioma cells. Mechanistically, ACYP2 promoted malignant progression of glioma cells through regulating intracellular Ca2+ homeostasis via its interaction with PMCA4, thereby activating c-Myc and PTP1B/STAT3 signals. This could be effectively reversed by Ca2+ chelator BAPTA-AM or calpain inhibitor calpeptin. Conclusions: Our data demonstrate that ACYP2 functions as an oncogene in glioma through activating c-Myc and STAT3 signals via the regulation of intracellular Ca2+ homeostasis, and indicate that ACYP2 may be a potential therapeutic target and prognostic biomarker in gliomas.

References Powered by Scopus

A randomized trial of bevacizumab for newly diagnosed glioblastoma

2220Citations
N/AReaders
Get full text

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

2040Citations
N/AReaders
Get full text

CBTRUS statistical Report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012

1787Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Calcium signaling in cancer progression and therapy

42Citations
N/AReaders
Get full text

Plasma membrane Ca<sup>2+</sup> pump isoform 4 function in cell migration and cancer metastasis

5Citations
N/AReaders
Get full text

ACYP1 Is a Pancancer Prognostic Indicator and Affects the Immune Microenvironment in LIHC

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, M., Ruan, B., Wei, J., Yang, Q., Chen, M., Ji, M., & Hou, P. (2020). ACYP2 contributes to malignant progression of glioma through promoting Ca2+efflux and subsequently activating c-Myc and STAT3 signals. Journal of Experimental and Clinical Cancer Research, 39(1). https://doi.org/10.1186/s13046-020-01607-w

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

86%

Researcher 1

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

44%

Social Sciences 2

22%

Biochemistry, Genetics and Molecular Bi... 2

22%

Materials Science 1

11%

Save time finding and organizing research with Mendeley

Sign up for free